This phase I trial is assessing simultaneous radiotherapy and immunotherapy (with durvalumab) in patients with relapsed Diffuse Large B Cell Lymphoma.
This trial is treating patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma.
This is a radiotherapy and systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase I Dose Escalation Study of Radiotherapy and Durvalumab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Other Non-Commercial Sponsor
Patients enrolled in this trial will be allocated to a radiotherapy dose and site cohort at registration. There will be no intra-patient dose or site escalations. The number of anatomical sites and dose of radiotherapy will be escalated subject to safety. A fixed dose of durvalumab will be administered intravenously every 4 weeks.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More